NinePointTwo Capital’s Vir Biotechnology VIR Stock Holding History

NinePointTwo Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,466	Closed	-$298K	–	264
2022 Q3	$298K	Buy	+15,466	New	+$393K	0.12%	101

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NinePointTwo Capital's VIR Position: Q4 2022 in Review

NinePointTwo Capital sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 15,466 shares — an estimated $298K sold.

NinePointTwo Capital first reported a position in VIR in Q3 2022 and held it in 1 quarter. The position peaked at $298K in Q3 2022. 224 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

NinePointTwo Capital reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
NinePointTwo Capital sold 15,466 Vir Biotechnology shares in Q4 2022, an estimated $298K.
NinePointTwo Capital first reported a position in Vir Biotechnology in Q3 2022 and held it in 1 quarter.
NinePointTwo Capital's Vir Biotechnology position peaked at $298K in Q3 2022.
224 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on NinePointTwo Capital's 13F filing for Q4 2022, filed 14 Feb 2023.